Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus subtilis
- Development stage
- Phase 4
- Lead developer
- BASF
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
*Bacillus subtilis* is a Gram-positive, aerobic, spore-forming bacterium widely utilized as a probiotic and live biotherapeutic product. It functions by restoring intestinal microbial balance, inhibiting the growth of pathogenic bacteria through competitive exclusion and the production of antimicrobial lipopeptides (such as surfactin), and modulating host immune responses. In clinical practice, it is frequently used to treat diarrhea, irritable bowel syndrome (IBS), and intestinal dysbiosis, often formulated in combination with other probiotics like *Enterococcus faecium*. Beyond gastrointestinal health, *B. subtilis* is being investigated for neuroprotective effects in neurodegenerative diseases like Parkinson's disease, where it may activate the p38 MAPK/Nrf2 signaling pathway to prevent alpha-synuclein aggregation. Additionally, it serves as a recombinant delivery platform for oral vaccines, such as DreamTec's COVID-19 vaccine candidate, which expresses the SARS-CoV-2 spike protein on the spore surface to elicit an immune response.
- Brand names
- Medilac-VitaMedilac-SBio-Subtil
- Other names
- 枯草杆菌枯草芽孢杆菌B. subtilis
02
Targets
SARS-CoV-2 spikeNFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on bacillus subtilis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus subtilis.